Anti-ClfA Antibody Engineering for Broad S. aureus Strain Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Staphylococcus aureus infections, particularly those resistant to antibiotics, lack effective compositions and methods for targeting ClfA and alpha toxin, which are key virulence factors, leading to reduced efficacy against diverse clinical isolates.
Innovation Solution
Development of antibodies and antigen-binding fragments specifically binding to Staphylococcus aureus ClfA and alpha toxin, with optimized variable heavy and light chain complementarity determining regions, and Fc variants for enhanced affinity and stability, allowing for potent inhibition of bacterial agglutination and opsonophagocytic killing across multiple ClfA genotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a monoclonal antibody targets ClfA founder sequence ClfA002, then binding affinity and functional activity are reduced, but the antibody cannot effectively neutralize this virulence factor
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's complementarity determining regions (CDRs) to alter its binding parameters. Specifically, the antibody sequences were engineered to change their affinity and specificity parameters, enabling effective binding to multiple ClfA genotypes (ClfA001, ClfA002, ClfA004) rather than being limited to a single founder sequence, thus resolving the contradiction between binding affinity and strain coverage
Solution Approach 2:
The patent implements universality by designing a single monoclonal antibody that can recognize and bind to multiple ClfA genotypes and strains. The antibody exhibits broad-spectrum activity across diverse S. aureus strains including MRSA and CA-MRSA, making it a universal therapeutic that addresses multiple virulence factors simultaneously, thereby improving both binding affinity and adaptability
2Reliability
If empiric broad spectrum antibiotic therapy is used, then antibiotic resistance is fueled, but pathogen-specific treatment options are limited
Solution Approach 1:
The patent extracts the therapeutic focus from broad-spectrum antibiotics and isolates specific pathogen-targeting mechanisms. By developing monoclonal antibodies that specifically target ClfA and alpha toxin, the treatment complexity is reduced by eliminating the need for empiric therapy and focusing solely on the specific virulence factors of S. aureus, thereby improving treatment efficacy while simplifying the therapeutic approach
3Reliability
If multiple monoclonal antibodies target different virulence factors, then protection and strain coverage are enhanced, but the complexity of combination therapy increases
Solution Approach 1:
The patent merges the targeting of multiple virulence factors into a single monoclonal antibody molecule. The antibody simultaneously binds to ClfA (inhibiting fibrinogen binding and bacterial agglutination) and alpha toxin, providing multi-mechanistic protection against diverse S. aureus strains including MRSA and CA-MRSA, thereby achieving enhanced protection efficacy while simplifying the therapeutic formulation to a single agent rather than multiple combination therapies
Data Source
AI summary
The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.